trial

Individualized Pharmacological Approach to Obesity in Patients With Bipolar Disorder

NCTId NCT07213466
as of 2026-07-01
Add to landscapeMonitor thisAsk about this
at a glance
Phase 4 · Recruiting
Enrollment 100 (estimated)
Sponsored by Mayo Clinic
Primary completion 2028-02-01
Synthesized from structured facts only — each point cited above.

Design & status

Phase
Phase 4
Status
Recruiting
Enrollment
100 (estimated)
Study type
Interventional
Allocation
Non Randomized
Model
Parallel
Masking
None
Start
2026-01-19
Primary completion
2028-02-01
Eligibility
ALL · 18 Years · 65 Years

Interventions & indications

Drugs
Group Therapy ProgramSemaglutidePhentermine-Topiramatenaltrexone and bupropion (combination)

Sponsors

Mayo ClinicLead Sponsor
University of TorontoCollaborator

Investigators

1
Mark A Frye, M.D.Principal Investigator

Sites

1 total
Rochester, United States

Facts & assertions

4 sourced
Enrollment
100
Phase
PHASE4
Primary Completion Date
2028-02-01
Status
RECRUITING
relationships
The graph out of here
drug
Group Therapy Program
drug
Semaglutide
drug
Phentermine-Topiramate
drug
naltrexone and bupropion (combination)
drug
lead_sponsor
Mayo Clinic
company
collaborator
University of Toronto
company
indication
Schizo Affective Disorder
indication
Bipolar Disorder
indication
Obesity
indication
investigator
Mark A Frye, M.D.
person